Figure 5From: Systematic review and meta-analysis of Endostar (rh-endostatin) combined with chemotherapy versus chemotherapy alone for treating advanced non-small cell lung cancerTTP of Endostar combined with PBDC versus PBDC alone for treating NSCLC. PBDC, conventional platinum-based doublet chemotherapy; TTP, time to progression.Back to article page